Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	6,144	5,085	4,570	10,369	10,504	6,795
Short-Term Investments	1,709	1,523	1,546	849.2	274.5	729.9
Cash & Short-Term Investments	7,852	6,608	6,116	11,218	10,779	7,525
Cash Growth	23.02%	8.05%	-45.48%	4.08%	43.24%	13.00%
Accounts Receivable	2,134	2,053	1,609	1,563	1,442	1,137
Receivables	2,134	2,053	1,609	1,563	1,442	1,137
Inventory	1,765	1,687	1,205	738.8	460.6	353.1
Prepaid Expenses	720.5	736.2	459.2	537.6	431.6	442.1
Restricted Cash	10.6	-	-	-	-	5.1
Other Current Assets	60.8	117.1	206.5	86.1	121.9	98.6
Total Current Assets	12,544	11,201	9,596	14,144	13,235	9,561
Property, Plant & Equipment	3,328	3,083	2,585	1,453	1,456	1,424
Long-Term Investments	5,869	5,794	5,173	2,498	112.2	-
Goodwill	1,088	1,088	1,088	1,088	1,088	1,002
Other Intangible Assets	412.8	424.2	825.9	839.9	603.6	400
Long-Term Deferred Tax Assets	3,011	2,898	2,331	1,812	1,247	934.5
Long-Term Deferred Charges	-	66.6	62.6	58.9	40.2	-
Other Long-Term Assets	1,171	1,089	871.9	836.4	369.4	110.8
Total Assets	27,423	25,643	22,533	22,730	18,151	13,433

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	429.5	461.7	413	364.9	303.9	195
Accrued Expenses	3,179	2,782	2,584	2,556	2,003	1,467
Current Portion of Leases	-	82.8	92.3	83.7	89.4	80.2
Current Income Taxes Payable	-	103.1	161.1	99.5	123.3	211.3
Current Unearned Revenue	157	171.8	206.8	170.3	159.6	171.7
Other Current Liabilities	172.4	259.7	107.4	273.2	62.5	16.5
Total Current Liabilities	3,938	3,861	3,565	3,547	2,742	2,142
Long-Term Leases	1,978	1,953	1,657	724.7	810.3	887.2
Other Long-Term Liabilities	1,260	1,163	901.8	877.7	685.8	303.3
Total Liabilities	7,175	6,977	6,124	5,150	4,238	3,333

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	2.5	2.5	2.6	2.6	2.6	2.5
Additional Paid-In Capital	4,506	5,119	6,672	7,450	7,387	6,881
Retained Earnings	15,691	13,560	9,607	10,142	6,523	3,201
Comprehensive Income & Other	48.5	-15.9	127.8	-14.3	0.8	15.9
Total Common Equity	20,248	18,666	16,410	17,580	13,913	10,100
Shareholders' Equity	20,248	18,666	16,410	17,580	13,913	10,100
Total Liabilities & Equity	27,423	25,643	22,533	22,730	18,151	13,433

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,978	2,036	1,750	808.4	899.7	967.4
Net Cash (Debt)	11,664	10,284	9,474	12,908	9,991	6,558
Net Cash Growth	11.07%	8.55%	-26.60%	29.19%	52.36%	14.71%
Net Cash Per Share	45.52	39.86	36.74	49.55	38.56	25.23
Filing Date Shares Outstanding	253.46	254.03	256.79	258.31	257.09	254.58
Total Common Shares Outstanding	253.35	253.99	256.94	257.7	257.01	254.48
Working Capital	8,606	7,340	6,032	10,597	10,493	7,419
Book Value Per Share	79.92	73.49	63.87	68.22	54.13	39.69
Tangible Book Value	18,747	17,154	14,496	15,653	12,221	8,698
Tangible Book Value Per Share	74.00	67.54	56.42	60.74	47.55	34.18
Land	-	33.1	33.1	33.1	33.1	33.1
Buildings	-	483.8	461.2	928.6	903.1	892.5
Machinery	-	1,198	1,061	911.9	788.6	701
Leasehold Improvements	-	1,009	737.6	474.6	410.9	363.5

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 14, 2026

Data Sources Report a data error